Advertisement

Topics

Acorda Halts Enrollment in Late-Stage Parkinson’s Disease Trial Following Five Patient Deaths

10:45 EST 15 Nov 2017 | Speciality Pharma Journal

ARDSLEY, N.Y.–(BUSINESS WIRE)– Acorda Therapeutics, Inc.(Nasdaq:ACOR) today announced that it has increased the frequency of blood cell count monitoring for participants to weekly in its Phase 3 program of tozadenant for Parkinson’s disease. The Company took this action in response to cases of agranulocytosis, possibly drug-related, and in some cases associated with sepsis and death. Agranulocytosis …

Original Article: Acorda Halts Enrollment in Late-Stage Parkinson’s Disease Trial Following Five Patient Deaths

NEXT ARTICLE

More From BioPortfolio on "Acorda Halts Enrollment in Late-Stage Parkinson’s Disease Trial Following Five Patient Deaths"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...